Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine

Casey, David G., Todryk, Stephen, James, Tharappel, Lysaght, Joanne, Bateman, Andrew and Melcher, Alan A. (2003) Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine. Immunology, 110 (1). pp. 105-111. ISSN 0019-2805

Full text not available from this repository. (Request a copy)
Official URL: http://dx.doi.org/10.1046/j.1365-2567.2003.01726.x

Abstract

Antigenic cross-reactivity between certain tumours has allowed the development of more widely applicable, major histocompatibility complex-disparate (allogeneic) whole-cell vaccines. This principle should also allow heat shock proteins (hsp) derived from certain tumours (and carrying cross-reactive antigens) to be used as vaccines to generate anti-tumour immunity in a range of cancer patients. Here, hsp70 derived from gp70-antigen+ B16 melanoma generated cytotoxic-T-lymphocyte-mediated immune protection in BALB/c mice against challenge with gp70-antigen+ CT26 colorectal tumour cells. Using ovalbumin as a model tumour antigen, it is shown that hsp70 enhances peptide re-presentation by dendritic cells via class I over equimolar whole ovalbumin antigen. However, while transfection of tumour cells with inducible hsp70 increases hsp yield from tumours, it does not enhance antigen recognition via purified hsp70 nor via whole cells or their lysate.

Item Type: Article
Subjects: A300 Clinical Medicine
Department: Faculties > Health and Life Sciences > School of Life Sciences > Applied Sciences
Depositing User: EPrints Services
Date Deposited: 08 Jan 2009 12:33
Last Modified: 09 Mar 2016 11:36
URI: http://nrl.northumbria.ac.uk/id/eprint/1265

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics


Policies: NRL Policies | NRL University Deposit Policy | NRL Deposit Licence